A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

Sponsor
Eli Lilly and Company
Study ID
NCT05931380
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Orforglipron — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally

Study Details

The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.

Key Dates

Start date
Jul 31, 2023
Status verified
Aug 2025
Primary completion
Jun 19, 2025
Completion
Jun 19, 2025

Study Design

Enrollment
238 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Orforglipron Dose 1
    Participants will receive orforglipron orally.
  • Experimental: Orforglipron Dose 2
    Participants will receive orforglipron orally.
  • Experimental: Orforglipron Dose 3
    Participants will receive orforglipron orally.
  • Placebo Comparator: Placebo
    Participants will receive placebo.

Primary Outcome Measure

Mean Percent Change in Body Weight [ Time Frame: Baseline, Week 72 ]

Related coverage on Hipa.ai

Related Studies